Navigation Links
JCI table of contents: June 20, 2008
Date:6/20/2008

teaga and Jeffrey Engelman, generated cancer cells resistant to the effects of gefitinib and found that these cells were constantly sending signals from a protein on their surface known as IGF1R. This meant that two proteins known as IRS-1 and PI3K were always associated. If this association was disrupted then the cells once again became susceptible to the effects of gefitinib. Further analysis showed that if mice with a human tumor were treated with gefitinib and a drug inhibiting IGF1R their tumors did not recur, whereas neither drug alone could prevent tumor recurrence. The authors therefore suggest that drug combinations that target both EGFR and IGF1R might be of benefit to individuals with cancers that are responsive to EGFR-targeted therapies.

TITLE: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

AUTHOR CONTACT:
Carlos L. Arteaga
Vanderbilt University Medical Center, Nashville, Tennessee, USA
Phone: (615) 936-3524; Fax: (615) 936-1790; E-mail: carlos.arteaga@vanderbilt.edu.

Jeffrey A. Engelman
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts, USA.
Phone: (617) 724-7298; Fax: (617) 724-9648; E-mail: jengelman@partners.org.

View the PDF of this article at: https://www.the-jci.org/article.php?id=34588

ACCOMPANYING COMMENTARY

TITLE: Mechanisms of resistance to ErbB-targeted cancer therapeutics

AUTHOR CONTACT:
Mark I. Greene
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 898-2870; Fax: (215) 898-2401; Email: greene@reo.med.upenn.edu.

View the PDF of this article at:

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. JCI table of contents: Sept. 4, 2007
4. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
5. Actavis Launches Carvedilol Tablets in the U.S.
6. Mylan Announces Final FDA Approval for Carvedilol Tablets
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Actavis Launches Amlodipine Tablets in the U.S.
9. Implantable device designed to detect, stop seizures under study at MCG
10. Stevens Health, Technology and Society roundtable: Sept. 19
11. Fruity vegetables and fish reduce asthma and allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 (HealthDay News) -- Modern forensic techniques ... injuries might have killed King Richard III, the last ... analysis of the king,s skeletal remains, using whole-body CT ... detailed account of the 11 injuries he suffered at ... Aug. 22, 1485. The modern forensics revealed that ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. Michael ... one of the Top Doctors of 2014. The annual ... magazine serving the Houston area. They award esteemed doctors ... outstanding services. This accomplishment will be included in the ... a special publication listing all the winners of the ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a ... $10,000 in a 0% interest free, 2nd down payment assistance ... federal programs, are listed on their private website. The $10,000 ... or move out of the property. The down payment assistance ... no monthly payments paid by the Borrower. The money is ...
(Date:9/16/2014)... Denver, CO (PRWEB) September 16, 2014 ... today that it has been recognized for its high ... published Consulting magazine “The Best Small Firms to Work ... Firms survey annually, with more than 10,000 consultants participating ... Extensive employee satisfaction surveys were conducted, and firms ...
(Date:9/16/2014)... A new clinical trial comparing the ... balloons (DEB) in treating in-stent restenosis (ISR) ... superior late angiographic results and better late ... today at the 26th annual Transcatheter Cardiovascular ... Cardiovascular Research Foundation (CRF), TCT is the ...
Breaking Medicine News(10 mins):Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2
... drugs and end up in the ER, CDC says , ... accidental poisonings among American children can be found in the ... year in the United States, more than 71,000 children aged ... overdoses of prescription and over-the-counter drugs, the researchers found. , ...
... , , RANCHO CORDOVA, ... Blindness America announced today the results of their joint nationwide survey ... five 12 to 17-year-olds have difficulty seeing the classroom whiteboard/chalkboard, with ... noted even though nearly half (45 percent) of the children in ...
... , , PALM CITY, Fla., Aug. 4 ... pleased to announce that the Company has formed a partnership ... company. The agreement will enable InstantAmber to offer the ... a valuable information tool that gives parents the ability to ...
... , SADDLE BROOK, N.J., Aug. 4 ... ) is the only hospital in New Jersey and one ... amputees the new PROPRIO FOOT(R), a prosthesis that provides greater ... developed by Ossur, a global leader in orthopedic products, closely ...
... , , , GLENWOOD, Ill., ... recognized leader in personal and environmental radiation monitoring services, today reported financial results ... , Fiscal 2009 Third Quarter Highlights , ... $23.5 million on continued global demand for InLight products and increased domestic badge ...
... Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company ... of drugs, today announced that the Company has entered ... to establish a drug development center in China Medical ... as a platform for the development of innovative drug ...
Cached Medicine News:Health News:Medicines Top Source of Kids' Poisonings 2Health News:Medicines Top Source of Kids' Poisonings 3Health News:Medicines Top Source of Kids' Poisonings 4Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 2Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 3Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 4Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 2Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 3Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 2Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 2Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 4Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 6Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 7Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 8Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 9Health News:AlphaRx and Venturepharm Announce Collaboration Agreement 2
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
(Date:9/16/2014)... Sept. 16, 2014 Surgeons at The Children,s ... a case report the first successful use of a ... year-old boy with failing Fontan circulation to bridge him ... 3 years old, the patient received a Fontan circulation ... single ventricle. "The Fontan operation is the final planned ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
... June 20 GlaxoSmithKline,(NYSE: GSK ) today ... has extended the priority review period for PROMACTA(R),(eltrombopag) ... chronic idiopathic thrombocytopenic purpura, as they require more ... Fee action date has,been extended to September 19, ...
Cached Medicine Technology:PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5GSK Update on FDA Review of Promacta(R) (Eltrombopag) 2
19 Gauge. Reusable. Block of 4 each....
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 23 gauge, stainless steel probes with blunt tips. Probes are 18 cm (7.0 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto the ...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: